Biogen MA Inc. v. EMD Serono, Inc., No. 19-1133 (Fed. Cir. Sept. 28, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Please make the following changes: On page 8, lines 17–20, change “emphasized that whereas the attached carbohydrate groups in na- tive IFN-β protein were glycosolated, the attached carbohydrate groups in recombinant IFN -β were not glycosolated,” to —explained that the glycosyl- ation patterns in native IFN- β and reco mbinant IFN-β were different,—.